The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Natus Medical met expectations on revenue and met expectations on earnings per share.
Compared to the prior-year quarter, revenue increased slightly and GAAP earnings per share shrank to a loss.
Margins shrank across the board.
Natus Medical recorded revenue of $64.1 million. The four analysts polled by S&P Capital IQ foresaw net sales of $64.5 million on the same basis. GAAP reported sales were 0.9% higher than the prior-year quarter's $63.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.14. The three earnings estimates compiled by S&P Capital IQ anticipated $0.14 per share on the same basis. GAAP EPS were -$0.60 for Q4 compared to $0.19 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 55.4%, 630 basis points worse than the prior-year quarter. Operating margin was 3.6%, 1,250 basis points worse than the prior-year quarter. Net margin was -27.0%, 3,550 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $60.0 million. On the bottom line, the average EPS estimate is $0.06.
Next year's average estimate for revenue is $259.4 million. The average EPS estimate is $0.57.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,283 members out of 1,317 rating the stock outperform, and 34 members rating it underperform. Among 420 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 410 give Natus Medical a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Natus Medical is hold, with an average price target of $10.00.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Natus Medical performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Natus Medical to My Watchlist.